The effects of
FKS-508 [
AF102B; cis-2-methylspiro(1,3-oxathiolane-5,3')
quinuclidine], a selective
M1 muscarinic receptor agonist, were examined to predict the possible activity on
memory disorders using a T-maze and radial-arm maze task in experimental
amnesia models. The
amnesia models were produced by bilateral intracerebroventricular injection of
ethylcholine aziridinium ion (
AF64A), a selective cholinotoxin, in rats. Repeated administrations of
FKS-508 (5 mg/kg/day, i.p.) for 5 weeks significantly ameliorated impaired performance of AF64A-treated rats (AF64A-rats) in a delayed alternation task in the T-maze. Repeated administrations of
FKS-508 (1 and 5 mg/kg/day, p.o.) for 5 weeks significantly ameliorated acquisition failures of AF64A-rats in a radial-arm maze task. Single administration of
FKS-508 (1 and 5 mg/kg, p.o.) significantly reduced the incorrect choices of AF64A-rats in a radial-arm maze task with 6 hr-delay time. No abnormalities in general behaviors, such as loss of appetite and
ataxia, were observed in rats treated with
FKS-508 repeatedly during 5 weeks. Our present results showed that
FKS-508 can ameliorate memory impairments in AF64A-rats with central
cholinergic hypofunction without causing any behavioral abnormalities.
FKS-508 may be considered as a candidate for the clinical examination of the
cholinergic hypothesis of
senile dementia of the Alzheimer type.